Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 232

1.

The relationship between bisphosphonate adherence and fracture: is it the behavior or the medication? Results from the placebo arm of the fracture intervention trial.

Curtis JR, Delzell E, Chen L, Black D, Ensrud K, Judd S, Safford MM, Schwartz AV, Bauer DC.

J Bone Miner Res. 2011 Apr;26(4):683-8. doi: 10.1002/jbmr.274.

2.

Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial.

Bauer DC, Black DM, Garnero P, Hochberg M, Ott S, Orloff J, Thompson DE, Ewing SK, Delmas PD; Fracture Intervention Trial Study Group..

J Bone Miner Res. 2004 Aug;19(8):1250-8.

3.

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.

Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE.

Lancet. 1996 Dec 7;348(9041):1535-41.

PMID:
8950879
4.

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

Liberman UA, Weiss SR, Bröll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M.

N Engl J Med. 1995 Nov 30;333(22):1437-43.

5.

Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

Chesnut CH 3rd, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schimmer RC, Delmas PD; Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE)..

J Bone Miner Res. 2004 Aug;19(8):1241-9.

6.

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial.

Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ.

JAMA. 1998 Dec 23-30;280(24):2077-82.

PMID:
9875874
7.

Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial.

Ensrud KE, Black DM, Palermo L, Bauer DC, Barrett-Connor E, Quandt SA, Thompson DE, Karpf DB.

Arch Intern Med. 1997 Dec 8-22;157(22):2617-24.

PMID:
9531231
8.

Effect of alendronate on the age-specific incidence of symptomatic osteoporotic fractures.

Hochberg MC, Thompson DE, Black DM, Quandt SA, Cauley J, Geusens P, Ross PD, Baran D; FIT Research Group..

J Bone Miner Res. 2005 Jun;20(6):971-6.

9.

Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases.

Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA, Silverman S.

Mayo Clin Proc. 2006 Aug;81(8):1013-22.

PMID:
16901023
10.

Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study.

Siris ES, Harris ST, Eastell R, Zanchetta JR, Goemaere S, Diez-Perez A, Stock JL, Song J, Qu Y, Kulkarni PM, Siddhanti SR, Wong M, Cummings SR; Continuing Outcomes Relevant to Evista (CORE) Investigators..

J Bone Miner Res. 2005 Sep;20(9):1514-24.

11.

Effect of alendronate for reducing fracture by FRAX score and femoral neck bone mineral density: the Fracture Intervention Trial.

Donaldson MG, Palermo L, Ensrud KE, Hochberg MC, Schousboe JT, Cummings SR.

J Bone Miner Res. 2012 Aug;27(8):1804-10. doi: 10.1002/jbmr.1625.

12.

Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.

Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR; FLEX Research Group..

JAMA. 2006 Dec 27;296(24):2927-38.

PMID:
17190893
13.
14.

Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group.

Hochberg MC, Ross PD, Black D, Cummings SR, Genant HK, Nevitt MC, Barrett-Connor E, Musliner T, Thompson D.

Arthritis Rheum. 1999 Jun;42(6):1246-54.

15.

Adherence to oral bisphosphonates and the risk of subtrochanteric and femoral shaft fractures among female medicare beneficiaries.

Wang Z, Ward MM, Chan L, Bhattacharyya T.

Osteoporos Int. 2014 Aug;25(8):2109-16. doi: 10.1007/s00198-014-2738-x.

16.

Risk of fracture among women who lose bone density during treatment with alendronate. The Fracture Intervention Trial.

Chapurlat RD, Palermo L, Ramsay P, Cummings SR.

Osteoporos Int. 2005 Jul;16(7):842-8.

PMID:
15580479
17.

[Bisphosphonate treatment prevents hip fractures in 70-79 year old women with osteoporotic vertebral fractures].

Netelenbos JC.

Ned Tijdschr Geneeskd. 2001 Jul 14;145(28):1336-8. Review. Dutch.

PMID:
11484428
18.

Healthy users, healthy adherers, and healthy behaviors?

Silverman SL, Gold DT.

J Bone Miner Res. 2011 Apr;26(4):681-2. doi: 10.1002/jbmr.384. No abstract available.

19.

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR; HORIZON Pivotal Fracture Trial..

N Engl J Med. 2007 May 3;356(18):1809-22.

20.

Factors associated with bisphosphonate treatment failure in postmenopausal women with primary osteoporosis.

Cairoli E, Eller-Vainicher C, Ulivieri FM, Zhukouskaya VV, Palmieri S, Morelli V, Beck-Peccoz P, Chiodini I.

Osteoporos Int. 2014 Apr;25(4):1401-10. doi: 10.1007/s00198-014-2619-3.

PMID:
24510095
Items per page

Supplemental Content

Support Center